Ministry of Food and Drug Safety begins investigation into hyperlipidemia treatment that Daewon Pharmaceutical is producing on consignment

Reporter Kim Jisun / approved : 2023-10-13 03:07:11
  • -
  • +
  • 인쇄

 

[Alpha Biz=(Chicago) Reporter Kim Jisun] The Ministry of Food and Drug Safety has launched an investigation into the cause of the report that other drugs are included in the hyperlipidemia treatment "Rosuvastatin" of Dongkuk Pharmaceutical, which is being commissioned by Daewon Pharmaceutical.

According to the Ministry of Food and Drug Safety on the 12th, a report was recently received that a digestive medicine product was found in the Rosuvastatin product box. There are two packages of Rosuvastatin, 15 pills each, one of which was for stomach medicine.

Rosuvastatin, a hyperlipidemia complex of Dongkuk Pharmaceutical, is a product commissioned by Daewon Pharmaceutical at Hyangnam Plant in Hwaseong, Gyeonggi-do.

Daewon Pharmaceutical Co. said it is conducting a full investigation into the manufacturing line that produced the product on the same day and Dongkuk Pharmaceutical Co. is recalling the product.

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

어플

주요기사

Bithumb Faces ‘Book-Entry Trading’ Concerns After Miscrediting Hundreds of Thousands of Bitcoins2026.02.07
Kolmar Korea Certified as Year’s First ‘Reshoring’ Company; To Invest 100 Billion KRW in Smart Factory Expansion2026.02.06
Court Dismisses Additional Lawsuits by Shareholders Over "Invossa" Controversy, Ruling in Favor of Kolon2026.02.06
Nvidia Delays China H200 Chip Exports Amid Ongoing Talks With U.S. Government2026.02.06
Naver Issues Formal Apology Over Exposure of Celebrities’ and Politicians’ Past "Ji-sik-iN" Posts2026.02.06
뉴스댓글 >

건강이 보이는 대표 K Medical 뉴스

HEADLINE

PHOTO

많이 본 기사